Immix Biopharma, Inc.
General ticker "IMMX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $282.2M (TTM average)
Immix Biopharma, Inc. follows the US Stock Market performance with the rate: 45.9%.
Estimated limits based on current volatility of 3.1%: low 8.35$, high 8.88$
Factors to consider:
- Total employees count: 21 (+16.7%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Significant losses, Clinical trial failure, Regulatory and compliance, Manufacturing supply, Financing unavailable
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [2.70$, 7.29$]
- 2026-12-31 to 2027-12-31 estimated range: [1.93$, 5.42$]
Financial Metrics affecting the IMMX estimates:
- Positive: with PPE of -6.3 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: negative Industry operating cash flow (median)
- Negative: Investing cash flow per share per price, % of -3.94 <= -2.60
- Negative: negative Industry operating income (median)
- Negative: Shareholder equity ratio, % of 89.47 > 81.92
- Negative: 0 < Industry inventory ratio change (median), % of 0
- Negative: -0.37 < Inventory ratio change, % of 0
- Negative: Industry earnings per price (median), % of -15.99 <= 0
Short-term IMMX quotes
Long-term IMMX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $16.14MM | $22.67MM | $29.96MM |
| Operating Income | $-16.14MM | $-22.67MM | $-29.96MM |
| Non-Operating Income | $0.57MM | $1.02MM | $0.56MM |
| R&D Expense | $8.74MM | $11.29MM | $16.26MM |
| Income(Loss) | $-15.57MM | $-21.66MM | $-29.40MM |
| Taxes | $0.03MM | $0.04MM | $0.04MM |
| Net Income(Loss)* | $-15.43MM | $-21.61MM | $-29.44MM |
| Stockholders Equity | $16.41MM | $13.25MM | $93.80MM |
| Assets | $19.93MM | $22.95MM | $104.84MM |
| Operating Cash Flow | $-11.37MM | $-14.60MM | $-23.93MM |
| Capital expenditure | $0.05MM | $1.18MM | $0.73MM |
| Investing Cash Flow | $-0.05MM | $-1.18MM | $-7.21MM |
| Financing Cash Flow | $15.46MM | $15.95MM | $107.39MM |
| Earnings Per Share** | $-0.89 | $-0.76 | $-0.89 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.